Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 3/20 | 0.37 |
| ▸ | LDHB | P07195 | 3/20 | 0.37 |
| ▸ | HMGCR | P04035 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5676597 | 0.95 | LDHA (0.38) | LDHALDHBHMGCRPTPN1PTPN11 | |
| SCHEMBL5589026 | 0.94 | LDHA (0.37) | LDHALDHBHMGCRPTPN1PTPN11 | |
| SCHEMBL5586817 | 0.90 | GABRA1 (0.32) | HMGCRPPARGPPARAPPARD | |
| SCHEMBL5677948 | 0.90 | PPARG (0.43) | PPARGPPARAPPARD | |
| SCHEMBL5680805 | 0.90 | ALOX5 (0.38) | LDHALDHBHMGCRPPARGPPARA | |
| SCHEMBL5589064 | 0.89 | HMGCR (0.41) | LDHALDHBHMGCRPTPN1PTPN11 | |
| SCHEMBL5920195 | 0.88 | ALOX5 (0.43) | LDHALDHBPTPN1PPARGPPARA | |
| SCHEMBL5588358 | 0.87 | PPARG (0.39) | PTPN1PPARGPPARAPPARD | |
| SCHEMBL5681236 | 0.86 | HMGCR (0.39) | LDHALDHBHMGCRPTPN1PTPN11 | |
| SCHEMBL5920075 | 0.86 | LDHA (0.39) | LDHALDHBHMGCRPTPN1PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | ZHAO BAIYI | 2006-02-16 | — | — | US | disclosed |
| EP-1620447-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | Exxonmobil Chemical Patents Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2003102006-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | COMT, CD69, SPR | LDHA 3482/4885LDHB 3990/4885HMGCR 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.